LOBEF (Lobe Sciences) Buyback Yield %: 0.00 (As of Jul. 09, 2026)


What is Lobe Sciences Buyback Yield %?

Lobe Sciences LOBEF -8.87% Buyback Yield % is 0.00 as of Jul. 09, 2026. The stock has 2 warning signs investors should review. Among 741 Biotechnology companies, Lobe Sciences ranks worse than 134952.63% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Lobe Sciences's current buyback yield was 0.00%.

Lobe Sciences Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Lobe Sciences's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lobe Sciences Buyback Yield % Chart

Lobe Sciences Annual Data
Trend Dec16 Dec17 Dec18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -32.25 0.00 -37.54 0.00 -2.57

Lobe Sciences Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.31 -5.16 -2.62 -3.17 0.00

LOBEF vs VRTX, REGN, ALNY: Buyback Yield % Comparison

For the Biotechnology subindustry, Lobe Sciences's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lobe Sciences Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lobe Sciences's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Lobe Sciences's Buyback Yield % falls into.


Lobe Sciences Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Lobe Sciences's Buyback Yield for the fiscal year that ended in Aug. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0.251) / 9.76823002
=-2.57%

Lobe Sciences's annualized Buyback Yield for the quarter that ended in Feb. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + -0.001) / 12.22393032
=0.01%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Lobe Sciences (LOBEF) has a Buyback Yield % of 0.00 as of Jul. 09, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Lobe Sciences and its competitors. According to the industry distribution chart, Lobe Sciences ranks #999999 out of 741 companies in the Biotechnology industry.
Is Lobe Sciences' Buyback Yield % too high?
Lobe Sciences' current Buyback Yield % is 0.00. Based on the distribution chart, Lobe Sciences ranks #999999 out of 741 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Lobe Sciences' Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lobe Sciences ranks #999999 out of 741 companies for Buyback Yield %. This places Lobe Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Lobe Sciences and its competitors. Lobe Sciences's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lobe Sciences stock overvalued right now?
Lobe Sciences (LOBEF) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Lobe Sciences (LOBEF), the current Buyback Yield % is 0.00 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lobe Sciences Business Description

Other Exchanges LOBE:GermanyLOBE:Canada
Address 1771 Robson Street, No. 1614, Vancouver, BC, CAN, V6G 3B7
Lobe Sciences Ltd is a biopharmaceutical company focused on using lipid technology that develop therapies for orphan and rare diseases. It commercializes Altemia MF, a medical food intended to address nutritional deficiencies associated with sickle cell disease. Through its subsidiaries, the company also holds a majority interest in the development of Conjugated Psilocin for potential use in neurological and psychiatric indications. The company operates in one reportable segment, being the biopharmaceutical development of new medicines.